clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Tuberculosis D014376 20 associated lipids
Stomach Ulcer D013276 75 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Hearing Loss, Sensorineural D006319 8 associated lipids
Otitis Media D010033 12 associated lipids
Carcinoma, Basal Cell D002280 6 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Adenocarcinoma D000230 166 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Granda Martín MJ et al. [Mycoplasma-associated acute hepatitis in an adult patient without pulmonary involvement]. Gastroenterol Hepatol pmid:24569138
Dharmalingam S et al. Relationship of plasmid profile with the antibiotic sensitivity pattern of Helicobacter pylori isolates from peptic ulcer disease patients in Chennai. Indian J Med Microbiol pmid:17643038
Morimoto S et al. Chemical modification of erythromycins. I. Synthesis and antibacterial activity of 6-O-methylerythromycins A. 1984 J. Antibiot. pmid:6706855
Pike VW et al. Semi-automated preparation of a 11C-labelled antibiotic--[N-methyl-11C]erythromycin A lactobionate. 1984 Int J Appl Radiat Isot pmid:6231252
Fernandes PB et al. In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide. 1986 Antimicrob. Agents Chemother. pmid:2949695
Segreti J et al. In vitro activity of A-56268 (TE-031) and four other antimicrobial agents against Chlamydia trachomatis. 1987 Antimicrob. Agents Chemother. pmid:2952061
Benson CA et al. In vitro activity of A-56268 (TE-031), a new macrolide, compared with that of erythromycin and clindamycin against selected gram-positive and gram-negative organisms. 1987 Antimicrob. Agents Chemother. pmid:2952063
Barry AL et al. In vitro activity of a new macrolide, A-56268, compared with that of roxithromycin, erythromycin, and clindamycin. 1987 Antimicrob. Agents Chemother. pmid:2952064
Chin NX et al. Activity of A-56268 compared with that of erythromycin and other oral agents against aerobic and anaerobic bacteria. 1987 Antimicrob. Agents Chemother. pmid:2953303
Bowie WR et al. In vitro activity of Ro 15-8074, Ro 19-5247, A-56268, and roxithromycin (RU 28965) against Neisseria gonorrhoeae and Chlamydia trachomatis. 1987 Antimicrob. Agents Chemother. pmid:2953304
Hanson CW et al. Regression analysis, proposed interpretative zone size standards, and quality control guidelines for a new macrolide antimicrobial agent, A-56268 (TE-031). 1987 J. Clin. Microbiol. pmid:2954995
Floyd-Reising S et al. In vitro activity of A-56268 (TE-031), a new macrolide antibiotic, compared with that of erythromycin and other antimicrobial agents. 1987 Antimicrob. Agents Chemother. pmid:2955742
Fernandes PB et al. Susceptibility testing of macrolide antibiotics against Haemophilus influenzae and correlation of in vitro results with in vivo efficacy in a mouse septicemia model. 1987 Antimicrob. Agents Chemother. pmid:2957954
Sasaki J et al. Microbial transformation of 6-O-methylerythromycin derivatives. 1988 J. Antibiot. pmid:2971032
Adachi T et al. 14-Hydroxy-6-O-methylerythromycins A, active metabolites of 6-O-methylerythromycin A in human. 1988 J. Antibiot. pmid:2971033
Waites KB et al. In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones. 1988 Antimicrob. Agents Chemother. pmid:2973283
Barry AL et al. Variability of clarithromycin and erythromycin susceptibility tests with Haemophilus influenzae in four different broth media and correlation with the standard disk diffusion test. 1988 J. Clin. Microbiol. pmid:2976773
Chang HR and Pechère JC In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondii. 1988 Antimicrob. Agents Chemother. pmid:2837140
Barry AL et al. In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin. 1988 Antimicrob. Agents Chemother. pmid:2840016
Adachi T et al. Crystal and molecular structure of (14R)-14-hydroxy-6-O-methylerythromycin A. 1989 J. Antibiot. pmid:2737946
Gorzynski EA et al. Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin. 1989 Antimicrob. Agents Chemother. pmid:2524998
Fernandes PB et al. New macrolides active against Streptococcus pyogenes with inducible or constitutive type of macrolide-lincosamide-streptogramin B resistance. 1989 Antimicrob. Agents Chemother. pmid:2523688
Fernandes PB et al. In vitro and in vivo activities of clarithromycin against Mycobacterium avium. 1989 Antimicrob. Agents Chemother. pmid:2530933
Kohno Y et al. Comparative pharmacokinetics of clarithromycin (TE-031), a new macrolide antibiotic, and erythromycin in rats. 1989 Antimicrob. Agents Chemother. pmid:2526615
Tinel M et al. Effects of clarithromycin on cytochrome P-450. Comparison with other macrolides. 1989 J. Pharmacol. Exp. Ther. pmid:2527301
Adachi T et al. Hydroxylation and N-demethylation of clarithromycin (6-O-methylerythromycin A) by Mucor circinelloides. 1989 J. Antibiot. pmid:2529234
Naik S and Ruck R In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex. 1989 Antimicrob. Agents Chemother. pmid:2817858
Faghih R et al. Synthesis and antibacterial activity of (9S)-9-dihydroclarithromycin. 1990 J. Antibiot. pmid:2147921
Perronne C et al. Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages. 1990 Antimicrob. Agents Chemother. pmid:2171421
Morimoto S et al. Chemical modification of erythromycins. III. In vitro and in vivo antibacterial activities of new semisynthetic 6-O-methylerythromycins A, TE-031 (clarithromycin) and TE-032. 1990 J. Antibiot. pmid:2139023
Kohno Y et al. Autobacteriographic studies of clarithromycin and erythromycin in mice. 1990 Antimicrob. Agents Chemother. pmid:2140497
Marchi E Comparative efficacy and tolerability of clarithromycin and amoxycillin in the treatment of out-patients with acute maxillary sinusitis. 1990 Curr Med Res Opin pmid:2140546
Scaglione F Comparison of the clinical and bacteriological efficacy of clarithromycin and erythromycin in the treatment of streptococcal pharyngitis. 1990 Curr Med Res Opin pmid:2140547
Morimoto S et al. Chemical modification of erythromycins. VI. Structure and antibacterial activity of acid degradation products of 6-O-methylerythromycins A. 1990 J. Antibiot. pmid:2141599
Hardy DJ et al. Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. 1990 Antimicrob. Agents Chemother. pmid:2143642
Cacciapuoti AF et al. Microbiological and pharmacokinetic studies of acyl demycinosyltylosin and related tylosin derivatives. 1990 J. Antibiot. pmid:2145254
Ferrero JL et al. Metabolism and disposition of clarithromycin in man. 1990 Jul-Aug Drug Metab. Dispos. pmid:1976065
Straneo G and Scarpazza G Efficacy and safety of clarithromycin versus josamycin in the treatment of hospitalized patients with bacterial pneumonia. 1990 Mar-Apr J. Int. Med. Res. pmid:2140330
Fraschini F Clinical efficacy and tolerance of two new macrolides, clarithromycin and josamycin, in the treatment of patients with acute exacerbations of chronic bronchitis. 1990 Mar-Apr J. Int. Med. Res. pmid:2140331
Anderson G Clarithromycin in the treatment of community-acquired lower respiratory tract infections. 1991 J. Hosp. Infect. pmid:1684979
Davey PG The pharmacokinetics of clarithromycin and its 14-OH metabolite. 1991 J. Hosp. Infect. pmid:1684980
King A and Phillips I A comparison of the in-vitro activity of clarithromycin, a new macrolide antibiotic, with erythromycin and other oral agents. 1991 J. Hosp. Infect. pmid:1684981
Wood MJ The tolerance and toxicity of clarithromycin. 1991 J. Hosp. Infect. pmid:1684982
Clarithro- and azithromycin--better erythromycins? 1991 Drug Ther Bull pmid:1665125
Rastogi N et al. Antimycobacterial spectrum of sparfloxacin and its activities alone and in association with other drugs against Mycobacterium avium complex growing extracellularly and intracellularly in murine and human macrophages. 1991 Antimicrob. Agents Chemother. pmid:1667250
Gu JW et al. Bactericidal activity of clarithromycin and its 14-hydroxy metabolite against Haemophilus influenzae and streptococcal pathogens. 1991 J Clin Pharmacol pmid:1837032
Hughes WT and Killmar JT Synergistic anti-Pneumocystis carinii effects of erythromycin and sulfisoxazole. 1991 J. Acquir. Immune Defic. Syndr. pmid:2016690
Rastogi N and Labrousse V Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex. 1991 Antimicrob. Agents Chemother. pmid:1828135
Ji B et al. Effectiveness of clarithromycin and minocycline alone and in combination against experimental Mycobacterium leprae infection in mice. 1991 Antimicrob. Agents Chemother. pmid:1828136
Lu MY et al. A polymer carrier system for taste masking of macrolide antibiotics. 1991 Pharm. Res. pmid:1829521
Perronne C et al. Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages. 1991 Antimicrob. Agents Chemother. pmid:1656860
Morgan DK et al. A reversed-phase high-performance liquid chromatographic method for the determination and identification of clarithromycin as the drug substance and in various dosage forms. 1991 J Pharm Biomed Anal pmid:1831386
Dautzenberg B et al. Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial. 1991 Am. Rev. Respir. Dis. pmid:1832527
Rotsch TD et al. Determination of clarithromycin as a contaminant on surfaces by high-performance liquid chromatography using electrochemical detection. 1991 Pharm. Res. pmid:1833731
Jorgensen JH et al. Activity of clarithromycin and its principal human metabolite against Haemophilus influenzae. 1991 Antimicrob. Agents Chemother. pmid:1834012
Truffot-Pernot C et al. Effect of pH on the in vitro potency of clarithromycin against Mycobacterium avium complex. 1991 Antimicrob. Agents Chemother. pmid:1834015
Hamedani P et al. The safety and efficacy of clarithromycin in patients with Legionella pneumonia. 1991 Chest pmid:1835689
Fernandez-Martin J et al. Pyrimethamine-clarithromycin combination for therapy of acute Toxoplasma encephalitis in patients with AIDS. 1991 Antimicrob. Agents Chemother. pmid:1836943
Gelber RH et al. Activities of various macrolide antibiotics against Mycobacterium leprae infection in mice. 1991 Antimicrob. Agents Chemother. pmid:1648889
Cogo R et al. [Dynamics of sIgA concentration in bronchial secretions in patients with COBP treated with clarithromycin]. 1991 Jan-Dec G Ital Chemioter pmid:1365564
De Punzio C et al. Isolation of Chlamydia trachomatis during IVF-ET. 1991 Jul-Aug Acta Eur. Fertil. pmid:1844324
Rehg JE Anti-cryptosporidial activity of macrolides in immunosuppressed rats. 1991 Nov-Dec J. Protozool. pmid:1667930
Hughes WT Macrolide-antifol synergism in anti-Pneumocystis carinii therapeutics. 1991 Nov-Dec J. Protozool. pmid:1818149
Logan RP et al. Clarithromycin and omeprazole for Helicobacter pylori. 1992 Lancet pmid:1353155
Hammerschlag MR et al. In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. 1992 Antimicrob. Agents Chemother. pmid:1324650
Paulsen P et al. Influence of azithromycin and other macrolides on the intracellular killing of Staphylococcus aureus by human polymorphonuclear leucocytes of healthy donors and a patient with Chédiak-Higashi syndrome. 1992 Chemotherapy pmid:1324831
Hardy DJ et al. Clarithromycin, a unique macrolide. A pharmacokinetic, microbiological, and clinical overview. 1992 Diagn. Microbiol. Infect. Dis. pmid:1530914
Chu S et al. Drug-food interaction potential of clarithromycin, a new macrolide antimicrobial. 1992 J Clin Pharmacol pmid:1531484
Cynamon MH and Klemens SP Activity of azithromycin against Mycobacterium avium infection in beige mice. 1992 Antimicrob. Agents Chemother. pmid:1329622
Ruf B et al. Acquired resistance of MAI to clarithromycin. 1992 Am. Rev. Respir. Dis. pmid:1533999
Chonmaitree T et al. Effect of viral respiratory tract infection on outcome of acute otitis media. 1992 J. Pediatr. pmid:1534364
Knothe H [Short-term therapy of acute respiratory and ORL infections with Clarithromycin]. 1992 Z Gesamte Inn Med pmid:9022402
Bale MJ et al. MIC quality control guidelines for Haemophilus susceptibility tests using cefdinir (FK482), cefepime, cefetamet, cefpirome, ceftibuten, fleroxacin, temafloxacin, clarithromycin, RP59500, and trospectomycin. 1992 J. Clin. Microbiol. pmid:1310329
Bahal N and Nahata MC The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin. 1992 Ann Pharmacother pmid:1318761
Berk SL New macrolide antibiotics. 1992 Ann. Intern. Med. pmid:1386966
Yajko DM et al. Comparison of the intracellular activities of clarithromycin and erythromycin against Mycobacterium avium complex strains in J774 cells and in alveolar macrophages from human immunodeficiency virus type 1-infected individuals. 1992 Antimicrob. Agents Chemother. pmid:1387302
de Lalla F et al. Clarithromycin-ciprofloxacin-amikacin for therapy of Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS. 1992 Antimicrob. Agents Chemother. pmid:1387303
Peters DH and Clissold SP Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. 1992 Drugs pmid:1379907
Calzolari E et al. The efficacy of clarythromycin (A-56268, TE-031) in the treatment of genital chlamydial infection. 1992 Drugs Exp Clin Res pmid:1306155
Klemens SP et al. Activity of clarithromycin against Mycobacterium avium complex infection in beige mice. 1992 Antimicrob. Agents Chemother. pmid:1336945
Ji B et al. Bactericidal activities of single or multiple doses of various combinations of new antileprosy drugs and/or rifampin against M. leprae in mice. 1992 Int. J. Lepr. Other Mycobact. Dis. pmid:1338596
Yajko DM In vitro activity of antimicrobial agents against the Mycobacterium avium complex inside macrophages from HIV1-infected individuals: the link to clinical response to treatment? 1992 Res. Microbiol. pmid:1455069
Omura S et al. [Research and development of clarithromycin]. 1992 Yakugaku Zasshi pmid:1469609
Chu SY et al. Clarithromycin pharmacokinetics in healthy young and elderly volunteers. 1992 J Clin Pharmacol pmid:1474166
Gelber RH et al. Clarithromycin at very low levels and on intermittent administration inhibits the growth of M. leprae in mice. 1992 Int. J. Lepr. Other Mycobact. Dis. pmid:1474290
Heifets LB et al. Bacteriostatic and bactericidal activities of gentamicin alone and in combination with clarithromycin against Mycobacterium avium. 1992 Antimicrob. Agents Chemother. pmid:1416852
Brown BA et al. Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system. 1992 Antimicrob. Agents Chemother. pmid:1416891
Biehle J and Cavalieri SJ In vitro susceptibility of Mycobacterium kansasii to clarithromycin. 1992 Antimicrob. Agents Chemother. pmid:1416897
Chu SY et al. Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral doses. 1992 Antimicrob. Agents Chemother. pmid:1489187
Araujo FG et al. Activity of clarithromycin alone or in combination with other drugs for treatment of murine toxoplasmosis. 1992 Antimicrob. Agents Chemother. pmid:1489188
Gan VN et al. Pharmacokinetics of a clarithromycin suspension in infants and children. 1992 Antimicrob. Agents Chemother. pmid:1489191
Sturgill MG and Rapp RP Clarithromycin: review of a new macrolide antibiotic with improved microbiologic spectrum and favorable pharmacokinetic and adverse effect profiles. 1992 Ann Pharmacother pmid:1421677
Denny FW Current management of streptococcal pharyngitis. 1992 J Fam Pract pmid:1453145
Schrock CG Clarithromycin vs penicillin in the treatment of streptococcal pharyngitis. 1992 J Fam Pract pmid:1453146
Chaisson R Clarithromycin is effective against M. avium complex in AIDS. 1992 Am Fam Physician pmid:1456199
Ji B et al. Selection of resistant mutants of Mycobacterium avium in beige mice by clarithromycin monotherapy. 1992 Antimicrob. Agents Chemother. pmid:1482155
Rastogi N and Goh KS Effect of pH on radiometric MICs of clarithromycin against 18 species of mycobacteria. 1992 Antimicrob. Agents Chemother. pmid:1482156
Rastogi N et al. Activity of clarithromycin compared with those of other drugs against Mycobacterium paratuberculosis and further enhancement of its extracellular and intracellular activities by ethambutol. 1992 Antimicrob. Agents Chemother. pmid:1482157
Derouin F et al. Synergistic activity of clarithromycin and minocycline in an animal model of acute experimental toxoplasmosis. 1992 Antimicrob. Agents Chemother. pmid:1482160
Takeda H et al. [A study to clarify the mechanism of the usefulness of the macrolides--the influence of clarithromycin to biofilm with P. aeruginosa]. 1992 Kansenshogaku Zasshi pmid:1363435